LENALIDOMIDE
lenalidomide 20 mg capsule, 21
LENALIDOMIDE (14610Y)
14610Y
Manner of administration:Oral
Restriction
Indication: Multiple myeloma
Treatment phase: Initial treatment as monotherapy or dual combination therapy with dexamethasone for
progressive disease
Restriction
Indication: Multiple myeloma
Treatment phase: Continuing treatment as monotherapy or dual combination therapy with dexamethasone
following initial treatment for progressive disease
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 21 | # of repeats: 0 | DPMQ: $796.93 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
|
|
|||||
|
|
|||||